Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27412809 | 1.00 | ADRB3 (0.39) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL497884 | 1.00 | ADRB3 (0.39) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL12379878 | 0.95 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL8160007 | 0.95 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL3369231 | 0.95 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL3369227 | 0.95 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL3787952 | 0.94 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4REN | |
| SCHEMBL3787944 | 0.94 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4REN | |
| SCHEMBL3787948 | 0.94 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4REN | |
| SCHEMBL8161544 | 0.92 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225249-B1 | PROCESS FOR THE PREPARATION OF A MACROCYCLE | HOFFMANN LA ROCHE (CH) | 2016-08-03 | — | — | EP | disclosed |
| EP-2323981-B1 | PROCESS FOR THE PREPARATION OF A MACROCYCLE | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2323981-B1 | PROCESS FOR THE PREPARATION OF A MACROCYCLE | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-8106187-B2 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106187-B2 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC (US) | 2012-01-31 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7910728-B2 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090163706-A1 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRB3 4326/4885ADRA2B 4470/4885ADRA2C 3995/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | ADRB3 4572/4885ADRA2B 4492/4885ADRA2C 4004/4885 |
| US-20090163706-A1 | Process for the preparation of a macrocycle | CTRL, PREP, RNASE1 | ADRB3 4455/4885ADRA2B 4384/4885ADRA2C 4215/4885 |
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ADRB3 4329/4885ADRA2B 4524/4885ADRA2C 4066/4885 |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | HABP2, CYP3A7, ACE | ADRB3 4757/4885ADRA2B 4720/4885ADRA2C 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.